GPLB · Green Planet Bioengineering Co Ltd

Green Planet Bioengineering Co Ltd is not an operating business — it is a dormant public shell corporation whose financial results reflect only the cost of maintaining its regulatory status. The $35.8K net loss in FY2025 is not a measure of business performance but of administrative upkeep: per Item 7 and Note 2, these expenses consist almost entirely of accounting, legal, and Exchange Act compliance costs required to remain a publicly reporting entity. This explains why both net income and operating cash flow are nearly identical negative values — there is no underlying business activity generating revenue, receivables, inventory, or payables; the $36.5K net cash outflow from operations is simply the mirror image of those incurred expenses, funded entirely by interest-free, unsecured advances from a related party (Global Funds Holdings Corp., its majority stockholder). The fact that cash remains at $0 — and that total current assets and liabilities net to zero — confirms the absence of any commercial infrastructure: no customers, no suppliers, no payroll, no capital assets. This structural emptiness is formally acknowledged in the auditors’ reports for both FY2025 and FY2024, which include explicit going-concern qualifications stating the company’s ability to continue depends entirely on continued support from that related party — with no assurance such support will persist. Management’s commentary offers no new strategic milestones, no disclosed acquisition pipeline, and no timeline for operational resumption; instead, it reiterates generic risk language about 'delay in effecting its business plans' if opportunities aren't identified 'in the near term.' Critically, the filing contains no forward-looking guidance, no segment disclosures (explicitly stating it has a single non-operating segment), and no discussion of market conditions or competitive positioning — because there is no business to position. The $0.00 EPS is not a rounding artifact but a structural reality: with no earnings, no shares issued or repurchased, and no dilutive instruments, per-share metrics are mathematically meaningless. Investors should recognize this filing not as a snapshot of performance but as a disclosure of stasis — where every dollar spent is a cost of waiting, and every financial metric is a proxy for duration of dormancy rather than operational health.